Showing results (61-70 of 185) with videos related to
Sort By:
Pageof 19
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 1, 2023
A review of economic issues for gene-targeted therapies: Value, affordability, and accessLouis P Garrison, Andrew W Lo, Richard S Finkel, et al.BMC Medicine|January 29, 2024
Is the price right? Paying for value today to get more value tomorrowSreeram V Ramagopalan, Jose Diaz, Grace Mitchell, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2008
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancerJosh J Carlson, Louis P Garrison, Scott D Ramsey, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.JAMA Otolaryngology-- Head & Neck Surgery|January 31, 2020
Development of a Sleep Apnea-Specific Health State Utility AlgorithmJonathan R Skirko, Kathryn T James, Louis P Garrison, et al.Journal of Cancer Research and Clinical Oncology|May 12, 2009
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysisJosh John Carlson, Louis P Garrison, Scott D Ramsey, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 14, 2022
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate CancerBoshen Jiao, Yaw A Nyame, Josh J Carlson, et al.Journal of Medical Economics|August 14, 2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United StatesRoman Casciano, Maruit Chulikavit, Allison Perrin, et al.Health Economics|June 26, 2019
Do cancer treatments have option value? Real-world evidence from metastatic melanomaMeng Li, Anirban Basu, Caroline S Bennette, et al.Molecular Oncology|March 21, 2012
Paying for personalized care: cancer biomarkers and comparative effectivenessRahber Thariani, David L Veenstra, Josh J Carlson, et al.Pageof 19